ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Oncology & ASCO 2019: Moving from Autologous to Allogeneic ACT Paradigms
ACT approaches have the possibilities of therapies with reduced safety concerns, a higher therapeutic index, as well as breadth of targets including solid tumours. More details here.
Increasing Predictability in Patient Recruitment
PharmaVOICE article featuring commentary from E.B. McLindon on the increasing complexity of protocol design & the importance of assessing patient & site burden.
The Perverse Incentive: A Unified Approach to Patient Engagement
Matthew McCarty at ICON establishes a greater unified approach to patient engagement, retention, and compliance through patient-facing technologies.
ICON Acquires MeDiNova Research Site in Europe & Africa
ICON has acquired a majority shareholding in MeDiNova Research, a site network with research sites in Europe and Africa.
The Digital Trial: How Technology Is Changing Trial Design, Start-Up And Close-Out
In this Clinical Informatics News article, featuring commentary from ICON's Marie McCarthy, leveraging technology to accelerate study close-out is discussed.
A Holistic Approach to Transforming Clinical Trials
PharmaVOICE presents a podcast featuring ICON expert Marie McCarthy & Chen Admati (Intel), discussing the use of emerging tech to improve the efficiency of R&D.
Patient Engagement Web Platform from ICON Bolsters Clinical Connectivity
An Outsourcing Pharma article featuring commentary from EB McLindon & Gretchen Goller, on ICON’s new web-based patient engagement platform.
US Healthcare Reform Scenarios
There has been growing interest among politicians & the public for significant change of the US healthcare system.
ICON Introduces New Platform for Potential Trial Participants
A Clinical Trials Arena article on ICON's new patient engagement platform, supporting people interested in participating in clinical trials.
Rare Disease Trials Q&A
A PME article discussing the challenges of rare disease trials, including those of recruitment and retention unique to rare disease studies.